Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.
Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.
Scope of the Report:
The classification according to the material of Human Rabies Immunoglobulin (IM) includes ERIG, HRIG, and the proportion of HRIG in 2017is about 86.7%, and the proportion is in increasing trend from 2013 to 2017.
For ERIGs, the dosage is 40 IU per kg body weight subject to a maximum of 3000 IU. For HRIGs, the dosage is 20 IU per kg body weight subject to a maximum of 1500 IU.
Human Rabies Immunoglobulin (IM) is widely used for the Category II Exposure and Category III Exposure, the most proportion of Human Rabies Immunoglobulin (IM) is used for Category III Exposure, and the proportion in 2017 is about 82.6%.
China is the largest sales place, with a sales market share nearly 61.4% in 2017, because of the population. North America enjoys 4.3% market share.
The worldwide market for Human Rabies Immunoglobulin (IM) is expected to grow at a CAGR of roughly 8.0% over the next five years, will reach 450 million US$ in 2024, from 290 million US$ in 2019, according to a new WMR study.
This report focuses on the Human Rabies Immunoglobulin (IM) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Sichuan Yuanda Shuyang
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
Category II Exposure
Category III Exposure
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Rabies Immunoglobulin (IM) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Human Rabies Immunoglobulin (IM), with price, sales, revenue and global market share of Human Rabies Immunoglobulin (IM) in 2017 and 2018.
Chapter 3, the Human Rabies Immunoglobulin (IM) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Rabies Immunoglobulin (IM) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Human Rabies Immunoglobulin (IM) market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Human Rabies Immunoglobulin (IM) sales channel, distributors, customers, research findings and conclusion, appendix and data source.